Celltrion Inc - ESG Rating & Company Profile powered by AI
The assessment of Celltrion Inc is prepared by All Street Sevva using advanced artificial intelligence. Alternative corporations in the scoring industry group for Celltrion Inc are shownin the table. If you are employed by Celltrion Inc and you wish to licence your ESG aseessment, please get in touch.
Celltrion Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 5.6; made up of an environmental score of 5.0, social score of 5.0 and governance score of 6.9.
5.6
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 579 | Tonix Pharmaceuticals Holding Corp | 5.7 | High |
| 579 | VIVA Biotech Holdings | 5.7 | High |
| 602 | Celltrion Inc | 5.6 | High |
| 602 | Adaptimmune Therapeutics PLC | 5.6 | High |
| 602 | Aligos Therapeutics Inc | 5.6 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Celltrion Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Celltrion Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Celltrion Inc report the average age of the workforce?
Sign up for free to unlockDoes Celltrion Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Celltrion Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Celltrion Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Celltrion Inc offer flexible work?
Sign up for free to unlockDoes Celltrion Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Celltrion Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Celltrion Inc conduct supply chain audits?
Sign up for free to unlockDoes Celltrion Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Celltrion Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Celltrion Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Celltrion Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Celltrion Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Celltrion Inc disclose water use targets?
Sign up for free to unlockDoes Celltrion Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Celltrion Inc have a product recall in the last two years?
Sign up for free to unlockDoes Celltrion Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Celltrion Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Celltrion Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Celltrion Inc disclose parental leave metrics?
Sign up for free to unlockDoes Celltrion Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Celltrion Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Celltrion Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Celltrion Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Celltrion Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Celltrion Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Celltrion Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Celltrion Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Celltrion Inc disclose its waste policy?
Sign up for free to unlockDoes Celltrion Inc report according to TCFD requirements?
Sign up for free to unlockDoes Celltrion Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Celltrion Inc disclose energy use targets?
Sign up for free to unlockDoes Celltrion Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Celltrion Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Celltrion Inc
These potential risks are based on the size, segment and geographies of the company.
Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.